NF-κB plays a significant role in RA pathology [3], and novel therapeutic strategies aimed at specific inhibition of key elements in the NF-κB activation pathway have been under development in recent years [4, 5]. The gene discussed is NFKB1; the disease is rheumatoid arthritis.